Di Ze Pharmaceuticals (688192.SH) is planning to issue H shares and list on the Hong Kong Stock Exchange.
Di Zhe Pharmaceutical (688192.SH) announced that in order to deepen its global strategy layout, enhance the company's international brand image, and further improve the company's core competitiveness, the company plans to issue overseas listed foreign shares (referred to as "H shares") and list them on the main board of The Stock Exchange of Hong Kong Limited (referred to as "Hong Kong Stock Exchange").
Di Zhe Pharmaceuticals (688192.SH) announced that, in order to deepen its global strategic layout, enhance the company's international brand image, and further improve its core competitiveness, the company plans to issue overseas listed foreign shares (referred to as "H shares") and list them on the main board of The Stock Exchange of Hong Kong Limited (referred to as "HKEx").
Related Articles
Henan Qingshuiyuan Technology (300437.SZ) plans to transfer the equity of its wholly-owned subsidiary Siweida Company.
Guangzhou Automobile Group (02238): Zheng Heng resigns from the position of deputy general manager.
Fujian Supertech Advanced Material (688398.SH) controlling shareholder plans to reduce its shareholding by no more than 3%.
Henan Qingshuiyuan Technology (300437.SZ) plans to transfer the equity of its wholly-owned subsidiary Siweida Company.
Guangzhou Automobile Group (02238): Zheng Heng resigns from the position of deputy general manager.
Fujian Supertech Advanced Material (688398.SH) controlling shareholder plans to reduce its shareholding by no more than 3%.
RECOMMEND
